Regeneron (REGN) Tops Q1 EPS by 50c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regeneron Reports First Quarter 2026 Financial and Operating Results
April 29, 2026 6:30 AM EDTFirst quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent® global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD® U.S. net sales increased 52% to $468 million; total EYLEA HD and EYLEA® U.S. net sales decreased 10% to $941 million GAAP EPS of $6.75, including $0.82 negative impact from IPR&D; non-GAAP EPS(a) of $9.47, including $0.80 negative impact from IPR&DEYLEA HD approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5... More
